

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s):	Benameur <i>et al.</i>	Examiner:	Aradhana Sasan
Filed:	January 23, 2004	Group Art Unit:	1609
Serial No.:	10/764,282	Docket No.:	1759.051A
Title:	PHARMACEUTICAL COMPOSITION FOR ORAL USE COMPRISING AN ACTIVE PRINCIPLE LIABLE TO UNDERGO A LARGE FIRST INTESTINAL PASSAGE EFFECT		

Confirmation No.: 9192

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dated: November 5, 2007

**AMENDMENT AND RESPONSE**

Dear Sir:

This is a response to the Final Office Action mailed on July 9, 2007. In light of a request for a 1-month extension and fee therefore, enclosed herewith, a response is required by November 9, 2007. Therefore, this response is timely filed. Applicants are filing a request for continued examination (RCE) under 37 CFR § 1.114 with this response.

**Amendments to the Claims** begin on page 2 of this paper.

**Remarks** begin on page 5.